Live Marvell Technology Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Rapport Therapeutics, Inc.

Get SEC filing alerts via email and in your feed for Rapport Therapeutics, Inc.

RAPP

Rapport Therapeutics, Inc.

About Rapport Therapeutics, Inc.

Rapport Therapeutics is a biotech company focused on developing small molecule precision medicines for neurological and psychiatric disorders. Its platform targets neuronal receptor complexes, such as TARP-8 and nAChRs, to create highly selective therapies with improved safety profiles. The company’s lead candidate, RAP-219, aims to treat focal epilepsy, bipolar disorder, and neuropathic pain by precisely modulating brain region-specific receptors, reducing side effects and drug interactions.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from Rapport Therapeutics, Inc.

1
1
Rapport Therapeutics, Inc. Rapport Therapeutics Reports $20 Million Collaboration Revenue in Q1 2026

Via official filing (AI summary) | 29 days ago | 0 comments

2
1
Rapport Therapeutics, Inc. Rapport Therapeutics Reports $111.5 Million Net Loss for 2025, Advances Clinical Programs

Via official filing (AI summary) | 3 months ago | 0 comments

3
1
Rapport Therapeutics, Inc. Rapport Therapeutics Reports $26.9 Million Net Loss in Q3 2025, Highlights R&D Progress

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
Rapport Therapeutics, Inc. Rapport Therapeutics Reports $26.7 Million Net Loss in Q2 2025, Driven by Increased R&D Expenses

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
Rapport Therapeutics, Inc. Rapport Therapeutics Reports $24.1 Million Net Loss in Q1 2025, Increases R&D Spending

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
Rapport Therapeutics, Inc. Rapport Therapeutics Reports $78.3 Million Net Loss for 2024, Increases R&D Spending

Via official filing (AI summary) | about 1 year ago | 0 comments

7
1
Rapport Therapeutics, Inc. Rapport Therapeutics Reports Financial Results, Advances Lead Product Candidate RAP-219

Via official filing (AI summary) | over 1 year ago | 0 comments